Gary Lee
Chief Tech/Sci/R&D Officer bij LYELL IMMUNOPHARMA, INC.
Vermogen: 28 321 $ op 31-03-2024
Profiel
Gary Lee is currently the Chief Scientific Officer at Lyell Immunopharma, Inc. He was previously the Vice President-Cell Therapy at Sangamo Therapeutics, Inc. from 2005 to 2018 and the Chief Scientific Officer at Senti Sub I, Inc. from 2018 to 2022.
He received his undergraduate degree from the California Institute of Technology and his doctorate from the University of California, Berkeley.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
LYELL IMMUNOPHARMA, INC.
0.00% | 09-02-2024 | 12 700 ( 0.00% ) | 28 321 $ | 31-03-2024 |
Actieve functies van Gary Lee
| Bedrijven | Functie | Begin |
|---|---|---|
| LYELL IMMUNOPHARMA, INC. | Chief Tech/Sci/R&D Officer | 31-01-2022 |
Eerdere bekende functies van Gary Lee
| Bedrijven | Functie | Einde |
|---|---|---|
Senti Sub I, Inc.
 Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Chief Tech/Sci/R&D Officer | 01-01-2022 |
| SANGAMO THERAPEUTICS, INC. | Corporate Officer/Principal | 01-10-2018 |
Opleiding van Gary Lee
| California Institute of Technology | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| LYELL IMMUNOPHARMA, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Senti Sub I, Inc.
Senti Sub I, Inc. BiotechnologyHealth Technology Senti Biosciences, Inc. develops novel therapeutics. It specializes in thetic biology, gene therapy and cell therapy. The company was founded by Timothy K. Lu, Wilson Wong, James J. Collins and Philip Lee in 2016 and is headquartered in South San Francisco, CA. | Health Technology |
